A Child 'Punished for Not Being Profitable...' -- A Mother's Comment
Comments on CIRM's stance on gene therapy and commercialization
Some readers have remarked on Monday’s item dealing with the California stem cell agency’s stance on issues involved in a company’s abandonment of a clinical trial for a succesful treatment of the bubble baby disease.
One comment came from a mother of a child with the affliction, medically known as ADA-SCID. She said, “We have fought hard to keep Jako…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.